Glenmark - The Purbottar

13 Aug

Glenmark launches FabiFlu 400mg

editor0 CommentsNorth EastGlenmark

Glenmark Pharmaceuticals said it will introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day. The 200 mg dosage of FabiFlu required patients to take 18 tablets on Day 1 (nine in the morning and nine in the evening), followed by 8 tablets each day thereafter for a maximum of 14 days. With the new 400 mg version, patients will now have a more relaxed dosage regimen, with 9 tablets…

24 Jul

Favipiravir: Phase 3 Clinical Trial

editor0 CommentsHealthGlenmark

Top-line results from a Phase 3 clinical trial of Favipiravir in mild to moderate COVID-19 patients have been announced by Glenmark Pharmaceuticals Limited. The trial was conducted across seven clinical sites in India. The open-label randomized, multicenter clinical trial, conducted in 150 patients, evaluated the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19. Glenmark’s Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm. 69.8%…

21 Jul

Glenmark calls overpricing charge baseless- Fabiflu

editor0 CommentsBusinessGlenmark

In a strong-worded reaction to the Drugs Controller General of India (DCGI)'s move to pull up drug major Glenmark on charges of alleged overpricing, false and misleading claims related to its COVID-19 drug Favipiravir, the company has responded to the apex drug controller saying it was "dismayed" over the careless, unsubstantiated allegations that are devoid of merits. In a letter to DCGI V.G. Somani, Glenmark said compared to other therapies approved for emergency use in COVID-19 in India, FabiFlu is much more economical and an effective treatment option. The estimated total cost of therapy for full course is only Rs 9,150, when compared to the prices of Remdesivir (Rs…

19 Jul

Glenmark launches Hypertension Awareness symbol

editor0 CommentsHealthGlenmark

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, launched the world’s first hypertension awareness symbol, in collaboration with Association of Physicians of India (API) and Hypertension Society of India (HSI). The symbol is developed in consultation with 50,000 leading doctors in the country, to raise awareness of the growing burden of hypertension and the need for timely screening. Glenmark has also pledged on-ground support to the cause, by committing to screen 5 million people for hypertension, through screening kiosks at corporate hospitals in all major metro cities. Further, a dedicated task force of 200 people has been set up to…

14 Jul

FabiFlu: Glenmark commences PMS study

editor0 CommentsBusiness, HealthFabiFlu, Glenmark

Glenmark has announced a price reduction of 27% for FabiFlu. The new MRP is Rs 75 per tab from the earlier Rs 103 per tab. The price reduction has been made possible through benefits gained from higher yields and better scale, as both the API and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country. Glenmark Pharmaceuticals has also announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed…